Policy / Pricing MFN affecting Swiss medicines access, says Interpharma PharmaphorumPharma groups have held back from submitting around a third of their new medicines for reimbursement in Switzerland, impeding patient access.Read full story pharminent August 13, 2026 (Last updated: August 21, 2026) Pharmaphorum Pharma groups have held back from submitting around a third of their new medicines for reimbursement in Switzerland, impeding patient access. Read full story Post navigation Previous: Prior Authorization Metrics Provide New Insights into Insurer Practices, but Gaps RemainNext: PTC takes a chance on Sangamo’s Fabry disease gene therapy Related Stories Policy / Pricing Prior Authorization Metrics Provide New Insights into Insurer Practices, but Gaps Remain pharminent August 13, 2026 Policy / Pricing Trump signs order that nearly halves childhood immunisation coverage pharminent August 11, 2026 Policy / Pricing US generic tariff reprieve on the rocks as Trump proposes 100% rate in 2028 pharminent July 22, 2026
